SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:5d94e332-9be1-497e-b47f-c4e34631f56c"
 

Search: onr:"swepub:oai:lup.lub.lu.se:5d94e332-9be1-497e-b47f-c4e34631f56c" > Thrombolysis in the...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Thrombolysis in the developing world: is there a role for streptokinase?

Butcher, Ken (author)
Shuaib, Ashfaq (author)
Saver, Jeffrey (author)
show more...
Donnan, Geoffrey (author)
Davis, Stephen M. (author)
Norrving, Bo (author)
Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine
Wong, K. S. Lawrence (author)
Abd-Allah, Foad (author)
Bhatia, Rohit (author)
Khan, Adnan (author)
show less...
 (creator_code:org_t)
2013-01-21
2013
English.
In: International Journal of Stroke. - : SAGE Publications. - 1747-4949 .- 1747-4930. ; 8:7, s. 560-565
  • Research review (peer-reviewed)
Abstract Subject headings
Close  
  • Intravenous thrombolysis with tissue plasminogen activator is the only proven acute therapy for ischemic stroke. This therapy has not been translated into clinical practice in the developing world primarily due to economic constraints. Streptokinase, a lower cost alternative thrombolytic agent, is widely available in developing countries where it is utilized to treat patients with acute coronary syndromes. Although this drug has previously been found to be ineffective in ischemic stroke, the lack of benefit may have been related to a number of factors related to trial design rather than the drug itself. Specific features of prior trial designs that may have adversely affected outcomes include a prolonged treatment window, inclusion of patients with established infarction on computed tomography scan, failure to treat excessive arterial pressures, a fixed dose of streptokinase, and concomitant use of antithrombotic medications. Given the lack of therapeutic alternatives in developing countries, a new trial of streptokinase in acute stroke, utilizing stricter inclusion criteria similar to those in more recent thrombolytic studies, appears warranted.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Keyword

acute stroke therapy
clinical trial
cost factors
developing
countries
ischemic stroke
thrombolysis

Publication and Content Type

for (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view